精神分裂症患者的肺炎风险、抗精神病药剂量与抗胆碱能负荷
这项基于芬兰全国登记数据的队列研究纳入61 889例精神分裂症患者,评估特定抗精神病药、剂量及抗胆碱能负荷与肺炎住院风险的关联。结果显示,单药治疗呈剂量依赖性增加肺炎风险,高抗胆碱能负荷药物及高剂量喹硫平、氯氮平、奥氮平与肺炎风险升高相关,而总体抗精神病药使用与肺炎无显著关联。
要点
- 单药抗精神病药治疗与肺炎风险升高相关,且呈剂量依赖性;联合用药未见此关联。
- 高抗胆碱能负荷的抗精神病药与肺炎风险升高相关(AHR 1.26)。
- 高剂量喹硫平、高/中剂量氯氮平及高剂量奥氮平与肺炎风险升高相关。
核心结论
- 在精神分裂症患者中,与肺炎相关的抗精神病药不仅包括氯氮平(剂量≥180 mg/d),还包括喹硫平(≥440 mg/d)和奥氮平(≥11 mg/d)。
- 单药抗精神病药治疗和高抗胆碱能负荷的抗精神病药与肺炎风险增加相关,且呈剂量依赖性。
- 这些发现呼吁针对需要高风险抗精神病药的精神分裂症患者采取预防策略。
研究设计与样本
- 这项队列研究从1972至2014年芬兰全国登记数据中识别年龄≥16岁的精神分裂症或分裂情感性障碍患者。
- 研究随访期为1996至2017年,数据分析时间为2022年11月4日至2023年12月5日。
- 暴露包括特定抗精神病药单药治疗、按剂量分层(低<0.6 DDD/天、中0.6至<1.1 DDD/天、高≥1.1 DDD/天)、抗精神病药联合用药及按抗胆碱能负荷分层。
- 主要结局为首次肺炎住院,采用调整的个体内Cox比例风险回归模型分析,以未使用抗精神病药为参照。
主要发现
- 研究纳入61 889例精神分裂症患者(平均[SD]年龄46.2[16.0]岁;男性31 104例[50.3%])。
- 随访22年间,8917例患者(14.4%)发生1次或以上肺炎住院,其中1137例(12.8%)在入院30天内死亡。
- 与未使用抗精神病药相比,总体使用抗精神病药与肺炎无显著关联(AHR 1.12;95%CI 0.99-1.26)。
- 与未使用抗精神病药相比,单药治疗与肺炎风险升高相关(AHR 1.15;95%CI 1.02-1.30;P=.03),且呈剂量依赖性;联合用药未见关联。
- 按抗胆碱能负荷分类,仅高抗胆碱能负荷药物与肺炎相关(AHR 1.26;95%CI 1.10-1.45;P<.001)。
关键数值与推荐
- 剂量分层标准:低剂量<0.6 DDD/天、中剂量0.6至<1.1 DDD/天、高剂量≥1.1 DDD/天。
- 抗胆碱能负荷分为低、中、高三级。
- 单药治疗与肺炎风险升高相关(AHR 1.15;95%CI 1.02-1.30;P=.03)。
- 高抗胆碱能负荷药物与肺炎风险升高相关(AHR 1.26;95%CI 1.10-1.45;P<.001)。
临床怎么用
- 作者认为,这些发现呼吁针对需要高风险抗精神病药的精神分裂症患者采取预防策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Antipsychotic drugs (particularly clozapine) have been associated with pneumonia in observational studies. Despite studies of the associations between antipsychotic use and incident pneumonia, it remains unclear to what degree antipsychotic use is associated with increased risk of pneumonia, whether dose-response associations exist, and what agents are specifically associated with incident pneumonia. OBJECTIVE: To estimate pneumonia risk associated with specific antipsychotics and examine whether polytherapy, dosing, and receptor binding properties are associated with pneumonia in patients with schizophrenia. DESIGN, SETTING, AND PARTICIPANTS: This cohort study identified patients with schizophrenia or schizoaffective disorder (hereafter, schizophrenia) aged 16 years or older from nationwide Finnish registers from 1972 to 2014. Data on diagnoses, inpatient care, and specialized outpatient care were obtained from the Hospital Discharge Register. Information on outpatient medication dispensing was obtained from the Prescription Register. Study follow-up was from 1996 to 2017. Data were analyzed from November 4, 2022, to December 5, 2023. EXPOSURES: Use of specific antipsychotic monotherapies; antipsychotics modeled by dosage as low (<0.6 of the World Health Organization defined daily dose [DDD] per day), medium (0.6 to <1.1 DDDs per day), or high dose (≥1.1 DDDs per day); antipsychotic polypharmacy; and antipsychotics categorized according to their anticholinergic burden as low, medium, and high. MAIN OUTCOMES AND MEASURES: The primary outcome was hospitalization for incident pneumonia. Pneumonia risk was analyzed using adjusted, within-individual Cox proportional hazards regression models, with no antipsychotic use as the reference. RESULTS: The study included 61 889 persons with schizophrenia (mean [SD] age, 46.2 [16.0] years; 31 104 men [50.3%]). During 22 years of follow-up, 8917 patients (14.4%) had 1 or more hospitalizations for pneumonia and 1137 (12.8%) died within 30 days of admission. Compared with no antipsychotic use, any antipsychotic use overall was not associated with pneumonia (adjusted hazard ratio [AHR], 1.12; 95% CI, 0.99-1.26). Monotherapy use was associated with increased pneumonia risk compared with no antipsychotic use (AHR, 1.15 [95% CI, 1.02-1.30]; P = .03) in a dose-dependent manner, but polytherapy use was not. When categorized by anticholinergic burden, only the use of antipsychotics with a high anticholinergic burden was associated with pneumonia (AHR, 1.26 [95% CI, 1.10-1.45]; P < .001). Of specific drugs, high-dose quetiapine (AHR, 1.78 [95% CI, 1.22-2.60]; P = .003), high- and medium-dose clozapine (AHR, 1.44 [95% CI, 1.22-1.71]; P < .001 and AHR, 1.43 [95% CI, 1.18-1.74]; P < .001, respectively), and high-dose olanzapine (AHR, 1.29 [95% CI, 1.05-1.58]; P = .02) were associated with increased pneumonia risk. CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that in patients with schizophrenia, antipsychotic agents associated with pneumonia include not only clozapine (at dosages ≥180 mg/d) but also quetiapine (≥440 mg/d) and olanzapine (≥11 mg/d). Moreover, monotherapy antipsychotics and antipsychotics with high anticholinergic burden are associated with increased pneumonia risk in a dose-dependent manner. These findings call for prevention strategies aimed at patients with schizophrenia requiring high-risk antipsychotics.
引用
- Luykx JJ, Correll CU, Manu P, et al. Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia. JAMA Psychiatry. 2024. PMID: 38922592. doi:10.1001/jamapsychiatry.2024.1441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。